Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Pathogenesis of human immunodeficiency virus infectionGenerating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticityNonhuman primate models for HIV/AIDS vaccine developmentCharacterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesStatistical analysis of sparse infection data and its implications for retroviral treatment trials in primates.Matrix-assisted laser desorption ionization/mass spectrometry mapping of human immunodeficiency virus-gp120 epitopes recognized by a limited polyclonal antibody.Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaquesLimited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimenEffective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimenCharacterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysVaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesDeterminants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeDifferences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primatesInduction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical TriaInduction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52DMonkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionHumoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression.Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virusVaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.Simian immunodeficiency virus DNA vaccine trial in macaques.Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals.The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolateFailure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strainHumoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
P2860
Q24531479-347C27B2-70FB-4D82-9882-8D6AF0DE3826Q24634681-0A539FFF-4C88-4F30-9F66-A4340EBA1C89Q24806405-F7ED20F5-E0A7-4063-8B51-6D2B2262B5CBQ26861148-E61FC81B-7AB9-446B-98DF-4BD230BA4715Q28646835-E390D283-923C-46FB-A725-EB0AB331DBBDQ28749120-23FA6427-D784-4017-84CD-AC80B9843A44Q30831495-BC6A096B-E74F-4142-862F-260F29387272Q32049913-1239ECC4-01D2-4EC2-8A4F-D9E535036B7DQ32157115-BACBF939-2865-4D94-8854-25A8AAF50019Q33555112-FA00E56B-9465-43A1-82CA-FE9673D8F730Q33639684-4875544E-3543-4381-A3E3-80F9C0B3FDE2Q33649842-887C0108-2F83-407C-8B69-4EA58932B86DQ33785114-24980ECF-E54C-4E32-B1DD-19982FCFA733Q33786386-637DEC8C-4D54-46A4-B44D-83E6456105A3Q33810203-F9CE0639-2B30-47B9-9B95-C575E282CDA9Q33819493-A3A925A4-4FB1-4CEC-B521-A21EFF4D5D79Q33821658-FF2386D3-5189-44DE-8AE1-4168595D1C0CQ33839402-90112DBA-5914-4EAA-AB23-712AE07D8F14Q33898692-FD28F42E-7DAE-4DDF-8991-22231250C31DQ33933098-FDB202D3-29F5-4998-BC8E-B1931200D7B3Q33933855-49A0F45D-8CE9-460B-BEBC-5A308383DB54Q34069214-56E5FFFD-537B-42BF-A0F1-9B4E8D5C2A24Q34119444-85A93B03-F55E-4D74-91E8-77FAEAD22341Q34171212-892CD07F-10CF-469A-A3EE-7BDBE7852A8CQ34171623-5E2A2564-4C2B-44C2-80C6-F8533BA1CF1FQ34323863-DC1F5C65-B62E-4ED0-9F21-376561035992Q35049812-2226979B-0263-449A-BB85-1E5E6531BC5FQ35170702-9331E2F7-4F37-4090-8DC2-CCD1D559D70EQ35224610-B0A5CAD1-77F0-4CBB-A524-E405BF5E2CD5Q35315868-EA94DFD2-9720-41C7-94C0-B454FA519B22Q35636394-63D43668-E5CD-4479-B35A-1526F6861237Q35833044-11217698-A06C-4E29-A14F-B36B09A47668Q35848078-E55F5E60-8EBC-4BF7-8216-6D8282373266Q35852493-1708F8A3-B699-48D5-8A3E-5606BC60E072Q35861970-13163ED6-E378-4E5F-AD0C-CAE77461A244Q35863652-25907868-D697-43E6-A56A-1D0260BC3F4FQ35869862-8450FE1A-A149-42E6-8090-B5465FB590EFQ35869892-7F66B88D-F9F5-4980-B280-2A6365A225A6Q35872988-1CAA170D-0449-4ACB-85D7-CA4F194CD2B3Q35881081-22E4A072-D3A0-444F-8FDB-EC35CFB78B20
P2860
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunization of chimpanzees co ...... h human immunodeficiency virus
@en
Immunization of chimpanzees co ...... human immunodeficiency virus.
@nl
type
label
Immunization of chimpanzees co ...... h human immunodeficiency virus
@en
Immunization of chimpanzees co ...... human immunodeficiency virus.
@nl
prefLabel
Immunization of chimpanzees co ...... h human immunodeficiency virus
@en
Immunization of chimpanzees co ...... human immunodeficiency virus.
@nl
P2093
P2860
P356
P1476
Immunization of chimpanzees co ...... h human immunodeficiency virus
@en
P2093
E Muchmore
T Reinhart
P2860
P304
P356
10.1073/PNAS.88.2.542
P407
P577
1991-01-01T00:00:00Z